
Researchers investigated the potential association between plasma apolipoprotein M (APOM) levels and the risk of adverse cardiovascular outcomes in individuals with chronic kidney disease (CKD). Plasma sphingosine-1-phosphate (S1P) levels were measured by high performance liquid chromatography (HPLC).


























